### 2025 Current Fiscal Year Report: Board of Scientific Counselors, National

Cancer Institute Report Run Date: 0	7/16/2025 10:25:2	0 AM	
1. Department or A	gency	2	2. Fiscal Year
Department of Heal Services	th and Human	2	2025
3. Committee or S	ubcommittee		3b. GSA Committee No.
Board of Scientific ( Cancer Institute	Counselors, Natior	nal 8	36
4. Is this New Duri	ng 5. Current 6.	Expected	7. Expected
Fiscal Year?	Charter Re	newal Date	Term Date
No	09/30/1994		
8a. Was Terminate FiscalYear?	d During Termina Authori	ation	8c. Actual Term Date
No			
9. Agency	<i></i>		10b.
Recommendation FiscalYear	for Next	gislation Terminate?	Legislation Pending?
	for Next	Terminate?	-
FiscalYear	Req to Not App	Terminate?	Pending?
FiscalYear Continue	Req to Not App	Terminate?	Pending? Not Applicable
FiscalYear Continue 11. Establishment	Not App Authority Author	Terminate? licable ized by Law	Pending? Not Applicable 14c.
FiscalYear Continue 11. Establishment 12. Specific	Not App Authority Author 13.	Terminate? licable ized by Law 14.	Pending? Not Applicable
FiscalYear Continue 11. Establishment 12. Specific Establishment	for Next Req to Not App Authority Author 13. Effective Date	Terminate? licable ized by Law 14. Commitee	Pending? Not Applicable 14c.
FiscalYear Continue 11. Establishment 12. Specific Establishment Authority	for Next Req to Not App Authority Author 13. Effective Date 11/04/1988	Terminate? licable ized by Law 14. Commitee Type Continuing	Pending? Not Applicable 14c. Presidential?
FiscalYear Continue 11. Establishment 12. Specific Establishment Authority 42 U.S.C. 284(c)(3) 15. Description of 16a. Total Number of	for Next Req to Not App Authority Author 13. Effective Date 11/04/1988	Terminate? licable ized by Law 14. Commitee Type Continuing	Pending? Not Applicable 14c. Presidential?
FiscalYear Continue 11. Establishment 12. Specific Establishment Authority 42 U.S.C. 284(c)(3) 15. Description of 16a. Total Number of Reports	for Next Req to Not App Authority Author 13. Effective Date 11/04/1988 Committee Other o Reports for s FiscalYear	Terminate? licable ized by Law 14. Commitee Type Continuing Committee	Pending? Not Applicable 14c. Presidential?
FiscalYear Continue 11. Establishment 12. Specific Establishment Authority 42 U.S.C. 284(c)(3) 15. Description of 16a. Total Number of Reports 17a. 0 17b. Close	for Next Req to Not App Authority Author 13. Effective Date 11/04/1988 Committee Other o Reports for s FiscalYear d0 17c. Partially	Terminate? licable ized by Law 14. Commitee Type Continuing Committee	Pending? Not Applicable 14c. Presidential? No

# Peer Review of Intramural<br/>Laboratories/Programs11/04/2024 - 11/04/2024Peer Review of Intramural<br/>Laboratories/Programs07/07/2025 - 07/08/2025

### Number of Committee Meetings Listed: 2

	Current FY	Next FY
18a(1). Personnel Pmts	\$17,600.00\$	17.600.00
to Non-Federal Members	ф, <b>ссс.сс</b> ф	,
18a(2). Personnel Pmts	\$0.00	\$0.00
to Federal Members	φ0.00	φ0.00
18a(3). Personnel Pmts	\$0.00	\$0.00
to Federal Staff	φ0.00	φ0.00
18a(4). Personnel Pmts		
to Non-Member	\$28,200.00\$	28,200.00
Consultants		
18b(1). Travel and Per		
Diem to Non-Federal	\$0.00	\$0.00
Members		
18b(2). Travel and Per		
Diem to Federal	\$0.00	\$0.00
Members		
18b(3). Travel and Per	\$0.00	\$0.00
Diem to Federal Staff	<i>Q</i> 0100	<i>Q</i> 0100
18b(4). Travel and Per		
Diem to Non-member	\$0.00	\$0.00
Consultants		
18c. Administrative		
Costs (FRNs, contractor		
support,	\$0.00	\$0.00
In-person/hybrid/virtual		
meetings)		
18d. Other (all other	• • • • • •	• • • • • •
funds not captured by	\$728.00	\$728.00
any other cost category)		
18e. Total Costs	\$46,528.00\$	46,528.00
19. Federal Staff Support	0.00	0.00
Years (FTE)		

## 20a. How does the Committee accomplish its purpose?

This committee is composed of recognized

biomedical and/or behavioral research authorities who represent the forefront of research and technical knowledge and who provide evaluation and peer review of Institute laboratories and staff scientists in the Center for Cancer Research and the Division of Cancer Epidemiology and Genetics.

## 20b. How does the Committee balance its membership?

The Board consists of up to 55 members, including Co-Chairs, appointed by the Director, NCI, from authorities knowledgeable in the fields of laboratory, clinical and biometric research; clinical cancer treatment; cancer etiology; cancer prevention and control with emphasis on training and experience in the various disciplines and fields related to scientific areas relevant to carcinogenesis; cancer biology and diagnosis; cancer center administration; medicine; radiological and surgical oncology; chemotherapy; cancer epidemiology, genetics, genomics, and related areas; cancer education; cancer information services; community outreach; biological, chemical and physical carcinogenesis; DNA repair; tumor biology and immunology; humoral and cellular immunity; hematopoiesis; cell differentiation and transformation; oncogenes and growth factors; molecular and structural biology; genetic regulation; cell signaling; viral oncology; vaccine development; transplantation; clinical trial design, management and evaluation; pharmacology; drug development and developmental therapeutics; proteomics; genetic and immunotherapies; pathology; diagnostic research and cytogenetics; biological response modifiers; imaging; nutrition; survey research; epidemiology; biostatistics; statistics; rehabilitation; psychology and behavioral

medicine; public health and community oncology; quality of life; pain management; cancer detection and diagnosis; cancer treatment and restorative care; dentistry; nursing; public health; education of health professionals; medical oncology; surgery; radiotherapy; gynecologic oncology; and pediatric oncology.

## 20c. How frequent and relevant are the Committee Meetings?

The Board meets approximately three times each fiscal year. The Board met on November 4, 2024, and July 7-8, 2025 for the overall program review of all Laboratories and Branches. Special site visit teams met 7 times to review and evaluate the program of individual laboratories and branches and advise on budget, staffing, and program strengths and weaknesses. Site Visit Dates: 10/7-9/2024, 10/16-18/2024, 10/30 - 11/1/2024, 11/19-20/2024, 11/20/2024, 3/3/2025, and 3/17-18/2025. \*Updated 4/22/2025

## 20d. Why can't the advice or information this committee provides be obtained elsewhere?

This Board is composed of recognized biomedical and behavioral research authorities from outside the NIH in order to secure unbiased and objective evaluations of intramural research programs. Their recommendations are invaluable because the complex nature of research in each laboratory requires a unique balance and breadth of expertise not available at NIH or from other established sources. This advice is essential for effective management of this Institute's intramural research programs.

## 20e. Why is it necessary to close and/or partially closed committee meetings?

The meetings of this Board were either closed or

partially closed to the public for the review, discussion, and evaluation of individual programs and projects conducted by the Divisions including consideration of personnel qualifications and performance, the competence of individual investigators, and similar items, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Section 552b(c)(6) of the Government in the Sunshine Act permits the closing of meetings where discussions could reveal personal information, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

#### 21. Remarks

Committee Function: Other - Scientific and Technical Peer Review. Reports: This committee did not produce any public reports. Members Rotating Off/On-Boarding: Five members rotated-off (William M. Clemons, Daphne A. Haas-Kogan, Barbara L. Kee, Alpa V. Patel, and Lewis R. Roberts) and XX were on-boarded. This is why the Charter states 55 potential members, but this ACR lists 26. \*Updated as of 04/22/2025 Members: The terms for Blossom A. Damania, Welkin E. Johnson, David R. Jones, and Tanya T. Paull have changed due to administrative extensions. As such, their terms of service end dates are different than what was reported on the FY24 ACR. William M. Clemons left the committee on 3/21/2025. As such, his term of service end date is different than what was reported on the FY24 ACR. The terms for William M. Clemons, Olivier Elemento, Daphne A. Haas-Kogan, Barbara L. Kee, Linda M. Liau, Alpa V. Patel, Lewis R. Roberts, and E. John Wherry have changed due to termination. As such, their terms of service end dates are different than what was reported on the FY24 ACR. \*Updated as of

04/22/2025 The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.

### **Designated Federal Officer**

Mehrdad M. Tondravi Chief, Institute Review Office, NCI

Committee Members	Start	End	Occupation	Member Designation
ADJEI, ALEX	02/27/2022	07/31/2026	CHAIRMAN, TAUSSIG CANCER INSTITUTE, M. FRANK RUDY AND MARGARET D. RUDY DISTINGUISHED CHAIR IN TRANSLATIONAL CANCER RESEARCH, CLEVELAND CLINIC	Special Government Employee (SGE) Member
BARTON, MICHELLE	03/24/2024	07/31/2028	Center, Knight Cancer Institute, Oregon Health and Science University	Special Government Employee (SGE) Member
BENVENISTE, ETTY	04/09/2023	07/31/2027	ASSOCIATE DIRECTOR FOR BASIC RESEARCH, O'NEAL COMPREHENSIVE CANCER CENTER, UNIVERSITY OF ALABAMA AT BIRMINGHAM	Special Government Employee (SGE) Member
BERG, LESLIE	02/27/2022	07/31/2026	PROFESSOR AND CHAIR, IMMUNOLOGY AND MICROBIOLOGY DEPARTMENT, UNIVERSITY OF COLORADO SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
CLEMONS, WILLIAM	05/21/2023	03/21/2025	ARTHUR AND MARIAN HANISCH MEMORIAL PROFESSOR OF BIOCHEMISTRY, DIVISION OF CHEMISTRY AND CHEMICAL ENGINEERING, CALIFORNIA INSTITUTE OF TECHNOLOGY	Special Government Employee (SGE) Member

DAMANIA, BLOSSOM	08/16/2020	07/26/2025	VICE DEAN FOR RESEARCH, SCHOOL OF MEDICINE, DIRECTOR, PROGRAMS IN VIROLOGY AND GLOBAL ONCOLOGY, LINEBERGER CANCER CENTER, UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	
DEBERARDINIS, RALPH	02/27/2022	07/31/2026	JOEL B. STEINBERG M.D. CHAIR IN PEDIATRICS, SOWELL FAMILY SCHOLAR IN MEDICAL RESEARCH, DEPARTMENT OF PEDIATRICS, UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	Special Government Employee (SGE) Member
DOHERTY, JENIFFER	04/09/2023	07/31/2027	HUNTSMAN CANCER INSTITUTE ENDOWED CHAIR IN CANCER RESEARCH, PROFESSOR, DIVISION OF CANCER POPULATION SCIENCES, DEPARTMENT OF POPULATION HEALTH SCIENCES, UNIVERSITY OF UTAH	Special Government Employee (SGE) Member
ELEMENTO, OLIVIER	09/10/2023	12/31/2025	PROFESSOR, DEPARTMENT OF PHYSIOLOGY AND BIOPHYSICS, DIRECTOR, ENGLANDER INSTITUTE FOR PRECISION MEDICINE, WEILL CORNELL MEDICINE	Special Government Employee (SGE) Member
GOODE, ELLEN	04/09/2023	07/31/2027	CONSULTANT, DIVISION OF EPIDEMIOLOGY, PROFESSOR OF EPIDEMIOLOGY, DEPARTMENT OF QUANTITATIVE HEALTH SCIENCES, COLLEGE OF MEDICINE, MAYO CLINIC	Special Government Employee (SGE) Member

GOODRICH, DAVID	12/05/2021	07/31/2026	DISTINGUISHED PROFESSOR OF ONCOLOGY, DEPARTMENT OF PHARMACOLOGY AND THERAPEUTICS, ROSWELL PARK CANCER INSTITUTE	Special Government Employee (SGE) Member
GUTKIND, SILVIO	05/19/2024	07/31/2028	Distinguished Professor and Chair, Department of Pharmacology, School of Medicine, University of California, San Diego	Special Government Employee (SGE) Member
HAAS-KOGAN, DAPHNE	02/27/2022	03/26/2025	CHAIR, DEPARTMENT OF RADIATION ONCOLOGY, BRIGHAM AND WOMEN'S HOSPITAL, DANA-FARBER CANCER INSTITUTE	Special Government Employee (SGE) Member
JOHNSON, WELKIN	12/17/2020	07/26/2025	PROFESSOR AND CHAIR, DEPARTMENT OF BIOLOGY, BOSTON COLLEGE	Special Government Employee (SGE) Member
JONES, DAVID	09/27/2020	07/26/2025	CHIEF, THORACIC SURGERY, DEPARTMENT OF SURGERY, MEMORIAL SLOAN KETTERING CANCER CENTER	Special Government Employee (SGE) Member
KEE, BARBARA	12/20/2021	03/26/2025	PROFESSOR, DEPARTMENT OF PATHOLOGY, UNIVERSITY OF CHICAGO	Special Government Employee (SGE) Member
LIAU, LINDA	07/15/2024	12/31/2025	W. EUGENE STERN PROFESSOR AND CHAIR, DEPARTMENT OF NEUROSURGERY, DAVID GEFFEN SCHOOL OF MEDICINE, UNIVERSITY OF CALIFORNIA, LOS ANGELES	Special Government Employee (SGE) Member
MALKIN, DAVID	02/27/2022	07/31/2026	ASSOCIATE CHAIR, DEPARTMENT OF MEDICAL BIOPHYSICS, PROFESSOR, DEPARTMENTS OF PEDIATRICS AND MEDICAL BIOPHYSICS, UNIVERSITY OF TORONTO	Government Employee (SGE)

MIGLIORETTI, DIANA	. 11/21/2021	07/31/2026	DEAN'S PROFESSOR, CHIEF, DIVISION OF BIOSTATISTICS, DEPARTMENT OF PUBLIC HEALTH SCIENCES, UNIVERSITY OF CALIFORNIA, DAVIS	Special Government Employee (SGE) Member
MOSCICKI, ANNA BARBARA	02/27/2022	07/31/2026	PROFESSOR OF PEDIATRICS, CHIEF, ADOLESCENT AND YOUNG ADULT MEDICINE, DAVID GEFFEN SCHOOL OF MEDICINE, UNIVERSITY OF CALIFORNIA, LOS ANGELES	Special Government Employee (SGE) Member
OLIVERA, BALDOMERO	06/21/2022	07/31/2026	DISTINGUISHED PROFESSOR, DEPARTMENT OF BIOLOGY, UNIVERSITY OF UTAH	Special Government Employee (SGE) Member
PARSONS, DONALD	05/19/2024	07/31/2028	Sidney L. and Donald F. Faust Chair of Pediatric Cancer Precision Medicine, Texas Children's Hospital, Professor, Department of Pediatrics, Baylor	Special Government Employee (SGE) Member
PATEL, ALPA	02/27/2022	03/26/2025	College of Medicine SENIOR VICE PRESIDENT, POPULATION SCIENCE, AMERICAN CANCER SOCIETY BURL G. AND LORENE	Special Government Employee (SGE) Member
PAULL, TANYA	12/17/2020	07/26/2025	L. ROGERS CHAIR IN HUMAN HEALTH, PROFESSOR, DEPARTMENT OF MOLECULAR GENETICS AND MICROBIOLOGY, THE UNIVERSITY OF	Special Government Employee (SGE) Member
RAPHAEL, BENJAMIN	07/31/2023	07/31/2027	TEXAS AT AUSTIN PROFESSOR, DEPARTMENT OF COMPUTER SCIENCE, PRINCETON UNIVERSITY	Special Government Employee (SGE) Member

ROBERTS, LEWIS	02/26/2023	03/26/2025	PETER AND FRANCES GEORGESON PROFESSOR OF GASTROENTEROLOGY CANCER RESEARCH, DIVISION OF GASTROENTEROLOGY AND HEPATOLOGY, DEPARTMENT OF INTERNAL MEDICINE, MAYO CLINIC	Government Employee
SARNOW, PETER	03/24/2024	07/31/2028	Burt and Marion Avery Professor of Immunology, Department of Microbiology and Immunology, Stanford University School of Medicine	Special Government Employee (SGE) Member
STRICKLAND, MATTHEW	04/11/2022	07/31/2026	PROFESSOR AND DIVISION LEAD, DIVISION OF EPIDEMIOLOGY, BIOSTATISTICS, AND ENVIRONMENTAL HEALTH, SCHOOL OF PUBLIC HEALTH, UNIVERSITY OF NEVADA, RENO	Special Government Employee (SGE) Member
VAN DEN BRINK, MARCEL	06/21/2022	07/31/2026	HEAD AND ALAN N. HOUGHTON CHAIR, DIVISION OF HEMATOLOGIC ONCOLOGY, MEMORIAL SLOAN KETTERING CANCER CENTER, PROFESSOR IN IMMUNOLOGY AND MEDICINE, WEILL CORNELL MEDICAL COLLEGE	Special Government Employee (SGE) Member
WHERRY, E.	01/26/2025	12/31/2025	Barbara and Richard Schiffrin President's Distinguished Professor, Chair, Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania	Special Government Employee (SGE) Member
ZÚÑIGA-PFLÜCKER, JUAN	04/07/2024	07/31/2028	Chair and Professor, Department of Immunology, Sunnybrook Research Institute, University of Toronto	Special Government Employee (SGE) Member

### **Narrative Description**

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. NIH works toward that mission by conducting research in its own laboratories. The mission of the Board of Scientific Counselors is to assess the quality of the Institute's intramural research programs and to evaluate the productivity and performance of intramural scientists in accordance with Section 492(b) of the PHS Act, as amended and shall also, as requested by the Director, NIH, undertake peer review of extramural funding applications as required by section 492(a) of the Public Health Service Act, as amended.

## What are the most significant program outcomes associated with this committee?

	Checked if Applies	
Improvements to health or safety		
Trust in government		
Major policy changes		
Advance in scientific research		✓
Effective grant making		
Improved service delivery		
Increased customer satisfaction		
Implementation of laws or regulatory		
requirements		
Other		

#### **Outcome Comments**

NA

### What are the cost savings associated with this committee?

**Checked if Applies** 

None

Unable to Determine	~
Under \$100,000	
\$100,000 - \$500,000	
\$500,001 - \$1,000,000	
\$1,000,001 - \$5,000,000	
\$5,000,001 - \$10,000,000	
Over \$10,000,000	
Cost Savings Other	

### **Cost Savings Comments**

NIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.

## What is the approximate <u>Number</u> of recommendations produced by this committee for the life of the committee?

709

### Number of Recommendations Comments

All the Laboratories/Branches reviewed in this fiscal year were either continued, expanded or closed. Continued means that there is not a change in scientific priorities or a decrease in the resources allocated to the laboratory/branch. Expanded means that the scientific priorities may be/are increased and thus an increase in resources are allocated to the laboratory/branch. Closed means that the scientific priorities are ended and the resources allocated to the laboratory/branch are decreased, i.e., towards closing the laboratory/branch.

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Fully</u> implemented by the agency? 90%

### % of Recommendations Fully Implemented Comments

The percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.

## What is the approximate <u>Percentage</u> of these recommendations that have been or will be Partially implemented by the agency?

10%

### % of Recommendations Partially Implemented Comments

The percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.

## Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes 🗹 No 🗌 Not Applicable 🗌

### Agency Feedback Comments

Information resulting from closed Board of Scientific Counselors meetings is subject to the Freedom of Information Act. The public can view information on NIH Intramural Research Reports found on the NIH Intramural Research Sourcebook website located at https://oir.nih.gov/sourcebook/intramural-research-communications-resources/annual-reports-bik

## What other actions has the agency taken as a result of the committee's advice or recommendation?

	Checked if Applies
Reorganized Priorities	$\checkmark$
Reallocated resources	$\checkmark$
Issued new regulation	
Proposed legislation	
Approved grants or other payments	
Other	

### **Action Comments**

The Scientific Director and other NIH/NCI officials use the recommendations made by the BSC in evaluating the quality of the intramural research programs including scientific priorities and resources available. As a result, all the Laboratories/Branches reviewed in this fiscal year were either continued, expanded or closed.

## Is the Committee engaged in the review of applications for grants? No

### **Grant Review Comments**

Although grant reviews are included in the duties of this Board, there were no grant reviews performed during this fiscal year.

### How is access provided to the information for the Committee's documentation?

	Checked if Applies
Contact DFO	$\checkmark$
Online Agency Web Site	$\checkmark$
Online Committee Web Site	✓
Online GSA FACA Web Site	✓
Publications	
Other	Y

### **Access Comments**

Contact the Designated Federal Officer.